Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Updated results of CameL-sq trial confirm benefit of camrelizumab

Updated results of CameL-sq trial confirm benefit of camrelizumab

Presented By
Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China
Presented by
Caicun Zhou Shanghai Pulmonary Hospital, China
Conference
ELCC 2022
Trial
Phase 3, CameL-sq
Doi
https://doi.org/10.55788/68905840
Updated results of the phase 3 CameL-sq trial continued to demonstrate that the addition of camrelizumab to first-line chemotherapy in patients with stage III–IV squamous non-small cell lung cancer (NSCLC) benefits survival. Several combinations of chemotherapy and immunotherapy are being evaluated as first-line treatment for patients with stage II–IV NSCLC. The phase 3 CameL-sq trial (NCT03668496) compared camrelizumab, a PD-1 inhibitor, plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel in patients with squamous NSCLC. Interim results revealed significantly prolonged progression-free survival (PFS: median 8.5 vs 4.9 months; P<0.0001) with camrelizumab plus chemotherapy. Overall survival (OS) data were not yet mature [1]. Now, Prof. Caicun Zhou (Shanghai Pulmonary Hospital, China) presented the results of an updated analysis [2]. The ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on